Form 4: ENZO Biochem CFO Sells Shares Post-Merger

ENZO Biochem's Chief Financial Officer, Patricia Eckert, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc.

Summary

• Patricia Eckert, Chief Financial Officer of ENZO Biochem Inc. (ENZB), reported changes in her beneficial ownership.
• The changes are a direct result of the Agreement and Plan of Merger, dated June 23, 2025, between ENZO Biochem, Bethpage Parent, Inc., and Bethpage Merger Sub, Inc., with the merger becoming effective on August 20, 2025.
• Eckert disposed of 28,328 shares of ENZO Biochem common stock.
• Each share of ENZO Biochem common stock was converted into the right to receive $0.70 in cash, without interest and less any applicable withholding taxes, as merger consideration.
• All of Eckert's outstanding stock options, totaling 275,000 shares (comprising 100,000, 75,000, 25,000, 50,000, and 25,000 options), were automatically canceled at the effective time of the merger without any cash payment or other consideration.

Sentiment

Score: 4

Explanation: The sentiment is neutral for common shareholders who received a cash payout, but negative for option holders, including the CFO, whose options were canceled without compensation, indicating a loss of potential value.

Positives

• The merger provided a cash payout of $0.70 per share for common stock holders.

Negatives

• Stock options held by the CFO, totaling 275,000 shares, were canceled without any compensation, indicating a loss of potential value for these equity incentives.

Risks

• Stock options were canceled without consideration, indicating they may have been out-of-the-money or the merger terms did not provide for their cash-out, resulting in a loss of potential value for option holders.

Future Outlook

This is a post-merger transaction report and does not contain forward-looking statements or guidance regarding the company's future operations or financial performance, as the company is now a wholly-owned subsidiary.

Industry Context

This filing reflects a completed corporate acquisition, a common occurrence in the biotechnology and diagnostics industry, where consolidation can occur to achieve scale, integrate technologies, or streamline operations. The acquisition of ENZO Biochem by Bethpage Parent, Inc. indicates a strategic move by the acquirer to potentially expand its market presence or acquire specific assets/capabilities from ENZO Biochem.

Comparison to Industry Standards

• The filing does not provide sufficient detail to compare the merger consideration or option treatment to specific industry benchmarks or comparable companies. The $0.70 per share cash consideration and the cancellation of stock options without payment are specific terms of this particular merger agreement. Without the full merger agreement or market context, a detailed comparison is not feasible.

Management Changes

Stakeholder Impact

• Shareholders: Received $0.70 per share in cash for their common stock.
• Option Holders (including management): Stock options were canceled without compensation, resulting in a loss of potential value.
• Employees: The filing does not provide information on the broader impact on employees beyond the CFO's equity holdings.

Next Steps

• The filing details a completed transaction and does not specify future actions or milestones for the reporting person or the now-acquired entity.

Key Dates

Keywords

ENZO Biochem, ENZB, Merger, Form 4, Beneficial Ownership, Stock Options, Common Stock, Patricia Eckert, Chief Financial Officer, Corporate Action